User:Mr. Ibrahem/Sotorasib

Sotorasib, sold under the brand names Lumakras and Lumykras, is a medication used to treat non-small-cell lung cancer (NSCLC). Specifically it is used for advanced disease that has a KRAS G12C-mutation and failed other treatments. It is taken by mouth.

Common side effects include diarrhea, musculoskeletal pain, nausea, tiredness, liver damage, and cough. Other side effects may include interstitial lung disease. Safety in pregnancy is unclear. It is an inhibitor of the RAS GTPase family, specifically the KRAS p.G12C mutation.

Sotorasib was approved for medical use in the United States in 2021 and Europe in 2022. In the United Kingdom a month of medication costs the NHS about £6900 as of 2022. This amount in the United States costs about 18,900 USD.